Drug
Gantenerumab clinical trials
Also written RO4909832.
How studies write it
Studies that test it under each name
Studies by the year they started
18 studies that test it; most in 2012 (4)
| Year | Studies |
|---|---|
| 2006 | 1 |
| 2010 | 1 |
| 2012 | 4 |
| 2014 | 2 |
| 2016 | 2 |
| 2017 | 1 |
| 2018 | 2 |
| 2020 | 3 |
| 2021 | 1 |
| 2022 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 15 · Other 3
Hoffmann-La Roche (14) · Washington University School of Medicine (3) · Chugai Pharmaceutical (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses gantenerumab is read from its arms, and is right about nine times in ten.
Testing it · 18
- Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation. Master Protocol DIAN-TU-001Active, not recruitingPhase 2/3Washington University School of MedicineNCT01760005Written as Gantenerumab
- A Study to Evaluate the Efficacy and Safety of Gantenerumab in Participants at Risk for or at the Earliest Stages of Alzheimer's Disease (AD)TerminatedPhase 3Hoffmann-La RocheNCT05256134Written as Gantenerumab
- Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia: A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic MutationTerminatedPhase 2/3Washington University School of MedicineNCT06424236Written as Gantenerumab
- A Study to Evaluate the Safety, Tolerability, and Efficacy of Long-Term Gantenerumab Administration in Participants With Alzheimer's Disease (AD)TerminatedPhase 3Hoffmann-La RocheNCT04374253Written as Gantenerumab
- A Study to Evaluate the Pharmacodynamic (PD) Effects of Once Weekly Administration of Gantenerumab in Participants With Early Alzheimer's Disease (AD)TerminatedPhase 2Hoffmann-La RocheNCT04592341Written as Gantenerumab
- Efficacy and Safety Study of Gantenerumab in Participants With Early Alzheimer's Disease (AD)TerminatedPhase 3Hoffmann-La RocheNCT03444870Written as Gantenerumab
- A Study to Evaluate the Safety and Tolerability of Long-term Administration of Gantenerumab in Participants With Alzheimer's Disease (AD)TerminatedPhase 3Hoffmann-La RocheNCT04339413Written as Gantenerumab
- Safety and Efficacy Study of Gantenerumab in Participants With Early Alzheimer's Disease (AD)TerminatedPhase 3Hoffmann-La RocheNCT03443973Written as Gantenerumab
- A Study of Gantenerumab in Participants With Mild Alzheimer DiseaseCompletedPhase 3Hoffmann-La RocheNCT02051608Written as Gantenerumab
- Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation.CompletedPhase 2/3Washington University School of MedicineNCT04623242Written as Gantenerumab
- A Study of Gantenerumab in Participants With Prodromal Alzheimer's DiseaseCompletedPhase 3Hoffmann-La RocheNCT01224106Written as Gantenerumab
- A Study to Assess the Impact of Speed and Site of Subcutaneous Injection on Pain, Tolerability, Safety, and Pharmacokinetics of Gantenerumab in Healthy ParticipantsCompletedPhase 1Hoffmann-La RocheNCT02882009Written as Gantenerumab
- A Single-Dose Study to Investigate the Safety, Tolerability, and Pharmacokinetics (PK) of Gantenerumab Following Subcutaneous (SC) Administration in Healthy VolunteersCompletedPhase 1Hoffmann-La RocheNCT02711423Written as Gantenerumab
- Relative Bioavailability of Gantenerumab Produced by G4 Process Versus G3 Process Following Subcutaneous (SC) Injection in Healthy ParticipantsCompletedPhase 1Hoffmann-La RocheNCT03236844Written as Gantenerumab
- A Study of A High Concentration Liquid Formulation Versus A Lyophilized Formulation of Gantenerumab in Healthy VolunteersCompletedPhase 1Hoffmann-La RocheNCT01636531Written as gantenerumab
- A Multiple Ascending Dose Study of R1450 in Patients With Alzheimer Disease.CompletedPhase 1Hoffmann-La RocheNCT00531804Written as gantenerumab
- A Study Investigating the Bioavailability of a High Concentration Liquid Formulation Versus a Reference Lyophilized Formulation of Gantenerumab in Healthy VolunteersCompletedPhase 1Hoffmann-La RocheNCT02133937Written as gantenerumab
- A Multiple-dose Study of Gantenerumab in Japanese Alzheimer&Apos;s Disease PatientsCompletedPhase 1Chugai PharmaceuticalNCT01656525Written as Gantenerumab
Codes
What other systems call gantenerumab · ClinicalTrials.gg INT006019
- MeSH (NLM) C571128gantenerumabOne source NLM
- UNII (FDA) 4DF060P933GANTENERUMABConfirmed FDA, NLM, Wikidata
- Wikidata Q3758140gantenerumabConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C88580GantenerumabOne source FDA
- DrugBank DB12034One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C571128 | gantenerumab | One source NLM |
| UNII (FDA) | 4DF060P933 | GANTENERUMAB | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q3758140 | gantenerumab | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C88580 | Gantenerumab | One source FDA |
| DrugBank | DB12034 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.